News Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program Staff June 25, 2022 Iframe sync Post navigation Previous: Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical UpdateNext: Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ More Stories Cancer Diagnostics DNA Medicare News Patient Care Pharmaceutical Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting Staff December 6, 2025 Cancer Clinical Trial News Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition Staff December 6, 2025 Cancer Clinical Trial News Pharmaceutical Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company’s RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma Staff December 6, 2025
